文献速递糖尿病

基于证据的2型糖尿病二甲双胍相互作用基因优先排序与富集分析

Evidence-based prioritisation and enrichment of genes interacting with metformin in type 2 diabetes.
PubMed 文献 · Diabetologia · 2017-08-25

研究通过自动文本挖掘构建二甲双胍-基因相互作用数据库(5963篇文献),对每个报道位点进行证据评分并排序,再在GoDARTS独立全基因组关联分析数据集中验证该基因集对血糖反应的富集程度。结果发现,最不优先类别(表达受二甲双胍影响的基因集)与二甲双胍血糖反应显著富集(p=0.03),包含SLC2A4(p=3.24×10⁻⁴)和G6PC(p=4.77×10⁻⁴)等新候选基因。

要点

  • 文本挖掘5963篇文献构建二甲双胍-基因相互作用数据库并进行证据评分。
  • 最不优先类别(表达受二甲双胍影响的基因集)与血糖反应显著富集(p=0.03)。
  • 该基因集包含SLC2A4(p=3.24×10⁻⁴)和G6PC(p=4.77×10⁻⁴)等新候选基因。

核心结论

  • 研究描述了半自动文本挖掘与证据评分算法,可促进基因-药物相互作用信息的组织与提取。
  • 在药物反应GWAS数据集中验证了该算法输出,提供了新的基因-二甲双胍相互作用候选位点。

研究设计与样本

  • 研究采用基于证据的多数据整合方法,使用自动文本挖掘方法构建已发表基因-二甲双胍相互作用数据库(n=5963篇文献)。
  • 对每个报道位点生成证据评分并产生排序基因集,再在GoDARTS独立全基因组关联分析(GWAS)数据集中进行复制分析以确定基因集对血糖反应的富集程度。

主要发现

  • 文献检索识别出7个与二甲双胍临床结局相关的基因。
  • 15个基因与二甲双胍药代动力学或药效动力学相关,另有51个基因的表达谱对二甲双胍有反应。
  • 由上述三个基因集及两个复合基因集组成的基因集富集分析显示,四个基因集无显著富集。
  • 最不优先类别(表达受二甲双胍影响的基因集)与二甲双胍血糖反应显著富集(p=0.03)。
  • 该基因集包含新候选基因SLC2A4(p=3.24×10⁻⁴)和G6PC(p=4.77×10⁻⁴)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: There is an extensive body of literature suggesting the involvement of multiple loci in regulating the action of metformin; most findings lack replication, without which distinguishing true-positive from false-positive findings is difficult. To address this, we undertook evidence-based, multiple data integration to determine the validity of published evidence. METHODS: We (1) built a database of published data on gene-metformin interactions using an automated text-mining approach (n = 5963 publications), (2) generated evidence scores for each reported locus, (3) from which a rank-ordered gene set was generated, and (4) determined the extent to which this gene set was enriched for glycaemic response through replication analyses in a well-powered independent genome-wide association study (GWAS) dataset from the Genetics of Diabetes and Audit Research Tayside Study (GoDARTS). RESULTS: From the literature search, seven genes were identified that are related to the clinical outcomes of metformin. Fifteen genes were linked with either metformin pharmacokinetics or pharmacodynamics, and the expression profiles of a further 51 genes were found to be responsive to metformin. Gene-set enrichment analysis consisting of the three sets and two more composite sets derived from the above three showed no significant enrichment in four of the gene sets. However, we detected significant enrichment of genes in the least prioritised category (a gene set in which their expression is affected by metformin) with glycaemic response to metformin (p = 0.03). This gene set includes novel candidate genes such as SLC2A4 (p = 3.24 × 10-04) and G6PC (p = 4.77 × 10-04). CONCLUSIONS/INTERPRETATION: We have described a semi-automated text-mining and evidence-scoring algorithm that facilitates the organisation and extraction of useful information about gene-drug interactions. We further validated the output of this algorithm in a drug-response GWAS dataset, providing novel candidate loci for gene-metformin interactions.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Dawed AY, Ali A, Zhou K, et al. Evidence-based prioritisation and enrichment of genes interacting with metformin in type 2 diabetes. Diabetologia. 2017. PMID: 28842730. doi:10.1007/s00125-017-4404-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。